SML3131

GSK620

≥98% (HPLC)

• 别名: 1-Benzyl-N5-cyclopropyl-N3-methyl-2-oxo-1,2-dihydropyridine-3,5-dicarboxamide, GSK 620, GSK-620, N5-Cyclopropyl-1,2-dihydro-N3-methyl-2-oxo-1-(phenylmethyl)-3,5-pyridinedicarboxamide
• 经验公式（希尔记法）: C₁₈H₁₉N₃O₃
• CAS号: 2088410-46-0
• 分子量: 325.36
• MDL编号: MFCD32899274
• UNSPSC代码: 51111800
• NACRES: NA.77

属性

• 质量水平: 100
• 方案: ≥98% (HPLC)
• 表单: powder
• 颜色: white to beige
• 溶解性: DMSO: 2 mg/mL, clear
• 储存温度: 2-8°C
• SMILES字符串: O=C1N(C=C(C=C1C(NC)=O)C(NC2CC2)=O)CC3=CC=CC=C3
• InChI key: QZZCUOVXHPAQRQ-UHFFFAOYSA-N

说明

生化/生理作用

GSK620 Is an orally active, potent and selective pan-second bromodomain (BD2) inhibitor (BD2/BD1 pIC50 = 6.5/4.6/BRD2, 7.1/4.6/BRD3, 7.1/4.8/BRD4, 6.7/4.6/BRDT) with improved oral availability than GSK046 (iBET-BD2) and in vivo efficacy in inflammatory disease models, including collagen-induced arthritis (3-10 mg/kg/d p.o. in rats), imiquimod (IMQ)-induced psoriasis (20 mg/kg/d p.o. in mice), and a nonalcoholic steatohepatitis (NAFLD) model (20 mg/kg/d p.o. in STAM mice).

Potent and selective pan-second bromodomain (BD2) inhibitor with in vivo efficacy in inflammatory disease models and improved oral availability than GSK046.

安全信息

• 储存分类代码: 11 - Combustible Solids
• WGK: WGK 3
• 闪点(°F): Not applicable
• 闪点(°C): Not applicable